CLASS II Device recall · Reported 8 Jul 2015 · FDA Enforcement Report

Etest Cefotaxime CT 256 WW and Etest Cefotaxime CT 256 US recalled

BioMerieux is recalling Etest Cefotaxime CT 256 WW and Etest Cefotaxime CT 256 US. in vitro diagnostic, distributed nationwide in the US. The recall was initiated on 12 Jun 2015 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codes1002774320, 1002377890, 1002590470, 1002775330, 1002379610
Quantity recalled674

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

Recall details

Recall number
Z-1947-2015
FDA event ID
71475
Recalling firm
BioMerieux, Marcy L'Etoile
Classification
Class II
Status
Terminated
Recall initiated
12 Jun 2015
FDA classified
1 Jul 2015
Reported
8 Jul 2015
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Other Reasons

Timeline

12 Jun 2015Recall initiated by company
1 Jul 2015Classified by FDA+19 days
8 Jul 2015Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

QC results were out of range resulting in false resistant strains.

Product as listed by the FDA

Etest Cefotaxime CT 256 WW and Etest Cefotaxime CT 256 US. in vitro diagnostic.

Where it was distributed

Worldwide Distribution - USA (nationwide) to the states of AL, AR, CA, CO, FL, GA, IL, IN, KY, MD, MI, MN, MO, NE, NY, NC, OH, OK, OR, PA, TN, TX, UT, VA, WA, WV and WI., and to the countries of: Austria, Australia, Canada, Switzerland, Germany, Spain, France, United Kingdom, Greece, Hong Kong, India, Italy, Japan, Netherlands, Poland, Sweden, Thailand, Turkey, Saudi Arabia, Philippines, Slovenia, Kuwait, Brazil, Chile, Czech Republic, Algeria, South Africa, Kosovo, Costa Rica, Belarus, Guam, Honduras and Vietnam.

Nationwide AlabamaArkansasCaliforniaColoradoFloridaGeorgiaIllinoisIndianaKentuckyMarylandMichiganMinnesotaMissouriNorth CarolinaNebraskaNew YorkOhioOklahomaOregonPennsylvania

Questions about this recall

Why was it recalled?

QC results were out of range resulting in false resistant strains.

Which lots are affected?

1002774320, 1002377890, 1002590470, 1002775330, 1002379610

Where was it sold?

Worldwide Distribution - USA (nationwide) to the states of AL, AR, CA, CO, FL, GA, IL, IN, KY, MD, MI, MN, MO, NE, NY, NC, OH, OK, OR, PA, TN, TX, UT, VA, WA, WV and WI., and to the countries of: Austria, Australia, Canada, Switzerland, Germany, Spain, France, United Kingdom, Greece, Hong Kong, India, Italy, Japan, Netherlands, Poland, Sweden, Thailand, Turkey, Saudi Arabia, Philippines, Slovenia, Kuwait, Brazil, Chile, Czech Republic, Algeria, South Africa, Kosovo, Costa Rica, Belarus, Guam, Honduras and Vietnam.

What should I do if I have it?

Stop using the device if the notice says to, and contact the manufacturer or your healthcare provider for the correction or replacement.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from BioMerieux

All 476

Other Test Kits & Diagnostics recalls

All 2,656